Spark Therapeutics, Inc. (NASDAQ:ONCE) – Analysts at William Blair issued their Q1 2018 earnings per share estimates for Spark Therapeutics in a research report issued to clients and investors on Tuesday. William Blair analyst R. Prasad forecasts that the biotechnology company will post earnings of ($1.99) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Spark Therapeutics’ Q2 2018 earnings at ($1.73) EPS, Q3 2018 earnings at ($1.09) EPS, Q4 2018 earnings at ($1.22) EPS and FY2018 earnings at ($6.02) EPS.

ONCE has been the subject of several other reports. Jefferies Group LLC assumed coverage on Spark Therapeutics in a report on Monday, July 10th. They issued a “buy” rating and a $85.00 price objective for the company. Cantor Fitzgerald lifted their price objective on Spark Therapeutics to $105.00 and gave the company an “overweight” rating in a report on Friday. Cowen and Company reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday. BidaskClub raised Spark Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Spark Therapeutics in a report on Friday. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $90.58.

ILLEGAL ACTIVITY WARNING: “Analysts Offer Predictions for Spark Therapeutics, Inc.’s Q1 2018 Earnings (ONCE)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/13/analysts-offer-predictions-for-spark-therapeutics-inc-s-q1-2018-earnings-once.html.

Shares of Spark Therapeutics (NASDAQ ONCE) traded down 0.97% on Thursday, hitting $85.36. The company had a trading volume of 1,204,764 shares. The company’s market capitalization is $2.67 billion. The firm has a 50-day moving average price of $85.92 and a 200 day moving average price of $85.92. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). The firm had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.04) earnings per share.

A number of hedge funds have recently modified their holdings of ONCE. Nationwide Fund Advisors grew its position in Spark Therapeutics by 2.5% during the 1st quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock worth $923,000 after acquiring an additional 414 shares during the last quarter. Bank of New York Mellon Corp grew its position in Spark Therapeutics by 10.9% during the 1st quarter. Bank of New York Mellon Corp now owns 111,043 shares of the biotechnology company’s stock worth $5,923,000 after acquiring an additional 10,916 shares during the last quarter. American International Group Inc. grew its position in Spark Therapeutics by 17.4% during the 1st quarter. American International Group Inc. now owns 11,582 shares of the biotechnology company’s stock worth $618,000 after acquiring an additional 1,714 shares during the last quarter. Cornerstone Capital Management Holdings LLC. bought a new stake in Spark Therapeutics during the 1st quarter worth $572,000. Finally, Principal Financial Group Inc. grew its position in Spark Therapeutics by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock worth $2,067,000 after acquiring an additional 122 shares during the last quarter. Institutional investors and hedge funds own 77.84% of the company’s stock.

In related news, insider Daniel Faga sold 1,500 shares of the business’s stock in a transaction on Tuesday, September 19th. The stock was sold at an average price of $85.00, for a total transaction of $127,500.00. Following the sale, the insider now owns 1,500 shares in the company, valued at approximately $127,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Katherine A. High sold 10,000 shares of the business’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $72.53, for a total value of $725,300.00. Following the sale, the insider now owns 220,000 shares in the company, valued at approximately $15,956,600. The disclosure for this sale can be found here. Insiders have sold a total of 1,333,195 shares of company stock worth $109,070,506 in the last 90 days. 7.30% of the stock is currently owned by corporate insiders.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.